• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | Registration & Listing | Adverse Events | Recalls | PMA | Classification | Standards | Inspections
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: this medical device record is a supplement. The device description may have changed. Be sure to look at the original PMA to get an up-to-date view of this device.
 
Trade NameS7 WITH DISCRETE TECHNOLOGY OVER-THE -WIRE CORONARY STENT SYSTEM/S7 WITH DISCRETE TECHNOLOGY RAPID EXCHANGE CORONARY
Classification Namestent, coronary
Generic Namecardiovascular stent
ApplicantMEDTRONIC VASCULAR
PMA NumberP970035
Supplement NumberS036
Date Received03/25/2002
Decision Date09/13/2002
Product Code
MAF[ Registered Establishments with MAF ]
Advisory Committee Cardiovascular
Supplement Typenormal 180 day track
Supplement Reason labeling change - instructions
Expedited Review Granted? No
Combination Product No
Approval Order Statement 
Approval for the following expanded device indications: the s7 with discrete technology over-the-wire coronary stent system with the av 2000 balloon is indicated for: "improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo lesions (length <= 30 mm) in native coronary arteries with reference vessel diameters ranting from 3. 0 mm to 4. 0 mm through direct stenting or predilatation. Long-term outcome (beyond 180-days) for this permanent implant is unknown at present. " the s7 with discrete technology over-the-wire coronary stent system with the av100 balloon is indicated for: "improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo lesions (length <= 30 mm) in native coronary arteries with reference vessel diameters ranging from 3. 0 mm to 4. 0 mm through direct stenting or predilatation. Long-term outcome (beyond 180 days) for this permanent implant is unknown at present. " the s7 with discrete technology rapid exchange coronary stent system with the av2000 balloon is indicated for: "improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo lesions (length <= 30 mm) in native coronary arteries with reference vessel diameters ranging from 3. 0 mm to 4. 0 mm through direct stenting predilatation. Long-term outcome (beyond 180 days) for this permanent implant is unknown at present. The rapid exchange delivery system will allow for perfusion at an average rate of 2 cc/min at nominal pressure during the 15-30 second stent deployment procedure only. The rapid exchange stent delivery system is not intended for use as a stand-alone ptca perfusion catheter. " the s7 with discrete technology rapid exchange coronary stent system with the av100 balloon is indicated for: "improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo lesions (length <= mm) in.
-
-